Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBT (2019 - 2025)

Historic EBT for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$186.5 million.

  • BridgeBio Pharma's EBT fell 1353.27% to -$186.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$775.5 million, marking a year-over-year decrease of 7196.85%. This contributed to the annual value of -$542.2 million for FY2024, which is 1700.07% up from last year.
  • BridgeBio Pharma's EBT amounted to -$186.5 million in Q3 2025, which was down 1353.27% from -$181.7 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's EBT peaked at -$19.1 million during Q1 2024, and registered a low of -$266.2 million during Q4 2024.
  • Over the past 5 years, BridgeBio Pharma's median EBT value was -$162.2 million (recorded in 2023), while the average stood at -$153.3 million.
  • Its EBT has fluctuated over the past 5 years, first surged by 8659.48% in 2024, then tumbled by 64071.27% in 2025.
  • Quarter analysis of 5 years shows BridgeBio Pharma's EBT stood at -$180.6 million in 2021, then grew by 19.62% to -$145.1 million in 2022, then tumbled by 32.37% to -$192.1 million in 2023, then tumbled by 38.59% to -$266.2 million in 2024, then rose by 29.96% to -$186.5 million in 2025.
  • Its EBT was -$186.5 million in Q3 2025, compared to -$181.7 million in Q2 2025 and -$141.1 million in Q1 2025.